查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654203

乳房粗針切片活體組織切片市場規模、佔有率、趨勢分析報告：按技術、最終用途、地區、細分預測，2025-2030 年

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

乳腺粗針穿刺切片市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，到2030年全球乳房粗針穿刺切片市場規模預計將達到11.5億美元，預計2025年至2030年期間的複合年成長率為4.6%。

推動市場成長的關鍵因素是乳癌盛行率的不斷上升、定期進行乳房X光攝影檢查的廣泛推薦、個人意識的不斷增強以及在該領域進行的廣泛研究。這些因素共同促進了乳房粗針穿刺切片的需求和採用的增加，為未來幾年的顯著成長鋪平了道路。

此外，影像和切片檢查技術的不斷進步也促進了該行業的擴張。人們越來越認知到早期發現和診斷在改善患者預後方面的重要作用。事實證明，粗針穿刺切片比傳統開放性手術切片檢查具有明顯的優勢，包括侵入性較小、恢復時間更短、成本效益更高。

隨著早期檢測和診斷的需求不斷上升，粗針穿刺切片市場預計將顯著成長。該領域的最新創新研究包括使用對比乳房 X 光攝影引導的乳房活體組織切片，該技術利用 MRI 技術來可視化造影，例如乳房切片IMIM（乳房X光攝影醫院醫學研究所）的研究人員於 2022 年在《歐洲放射學》雜誌上發表的研究結果。

COVID-19 疫情為乳房粗針穿刺切片市場帶來了挑戰，也帶來了新的機會。不必要的程序的延遲已導致診斷結果降低以及對粗針穿刺切片的需求減少。但這次疫情凸顯了早期發現的重要性，並迫使醫療保健提供者優先考慮篩檢和切片檢查，從而導致需求復甦。

粗針穿刺切片市場報告重點

  • 2024 年以超音波為基礎的乳房切片部分佔最大收入佔有率，為 41.9%。該領域佔據主導地位的原因在於超音波引導切片檢查因其顯著的優勢而越來越受到偏好。
  • 醫院和診斷實驗室部門在 2024 年的收益佔有率最高，為 60.0%。
  • 學術和研究機構部門預計將見證粗針穿刺切片行業的指數級成長，2025 年至 2030 年的複合年成長率為 4.4%。
  • 2024 年北美乳房粗針穿刺切片產業的收入佔有率為 46.26%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 乳房粗針穿刺切片市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 粗針穿刺切片市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章 乳房粗針穿刺切片市場：按技術、估計和趨勢分析

  • 2024 年及 2030 年技術市場佔有率
  • 細分儀表板
  • 全球乳房粗針穿刺切片市場展望（按技術）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 乳房切片及 MRI
    • 超音波引導下乳房切片
    • 乳房 X 光攝影（立體定位）乳房切片
    • CT 引導下乳房切片
    • 其他基於圖像的乳房切片

5. 乳房粗針穿刺切片市場：最終用途、估計與趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球乳房粗針穿刺切片市場前景（依最終用途）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 醫院和診斷實驗室
    • 製藥和生物技術公司
    • 學術研究所

第6章乳癌粗針穿刺切片市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 2024 年主要企業的市場佔有率分析
    • Intact Medical Corporation
    • Ethicon Surgical Technologies
    • Gallini SRL
    • Leica Biosystems Nussloch GmbH
    • Hologic, Inc
    • Argon Medical Devices
    • Encapsule Medical Devices LLC
    • Cook Medical Incorporated
    • Becton, Dickinson and Company
    • CR Bard, Inc.
Product Code: GVR-4-68040-161-0

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

  • The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.
  • The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.
  • The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.
  • North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. End use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Breast Cancer Core Needle Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing prevalence of breast cancer
      • 3.2.1.2. Advancement in imaging technologies and biopsy techniques
      • 3.2.1.3. Rising inclination towards minimally invasive procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of core needle biopsy procedures
      • 3.2.2.2. Limited expertise and training
  • 3.3. Breast Cancer Core Needle Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Breast Cancer Core Needle Biopsy Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Breast Cancer Core Needle Biopsy Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. MRI-Based Breast Biopsy
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Fermentation Ultrasound-Based Breast Biopsy
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Mammography-Based (Stereotactic) Breast Biopsy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. CT-Based Breast Biopsy
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Other Image-Based Breast Biopsy
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Breast Cancer Core Needle Biopsy Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Breast Cancer Core Needle Biopsy Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals & Diagnostic Laboratories
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. Pharmaceutical & Biotechnology companies
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Academic & Research Institutes
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Breast Cancer Core Needle Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Target Disease Prevalence
      • 6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Target Disease Prevalence
      • 6.5.2.4. Competitive scenario
      • 6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Target Disease Prevalence
      • 6.5.3.4. Competitive scenario
      • 6.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Target Disease Prevalence
      • 6.6.1.4. Competitive scenario
      • 6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Target Disease Prevalence
      • 6.6.2.4. Competitive scenario
      • 6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Target Disease Prevalence
      • 6.6.3.4. Competitive scenario
      • 6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Target Disease Prevalence
      • 6.6.4.4. Competitive scenario
      • 6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Target Disease Prevalence
      • 6.6.5.4. Competitive scenario
      • 6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Target Disease Prevalence
      • 6.6.6.4. Competitive scenario
      • 6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Target Disease Prevalence
      • 6.6.7.4. Competitive scenario
      • 6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Target Disease Prevalence
      • 6.6.8.4. Competitive scenario
      • 6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Target Disease Prevalence
      • 6.7.1.4. Competitive scenario
      • 6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Target Disease Prevalence
      • 6.7.2.4. Competitive scenario
      • 6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Target Disease Prevalence
      • 6.7.3.4. Competitive scenario
      • 6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Target Disease Prevalence
      • 6.7.4.4. Competitive scenario
      • 6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Target Disease Prevalence
      • 6.7.5.4. Competitive scenario
      • 6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Target Disease Prevalence
      • 6.7.6.4. Competitive scenario
      • 6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Target Disease Prevalence
      • 6.8.1.4. Competitive scenario
      • 6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Target Disease Prevalence
      • 6.8.2.4. Competitive scenario
      • 6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Target Disease Prevalence
      • 6.9.1.4. Competitive scenario
      • 6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Target Disease Prevalence
      • 6.9.2.4. Competitive scenario
      • 6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Target Disease Prevalence
      • 6.9.3.4. Competitive scenario
      • 6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Target Disease Prevalence
      • 6.9.4.4. Competitive scenario
      • 6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2024
    • 7.3.2. Intact Medical Corporation
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Ethicon Surgical Technologies
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Gallini SRL
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Leica Biosystems Nussloch GmbH
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Hologic, Inc
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Argon Medical Devices
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Encapsule Medical Devices LLC
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Cook Medical Incorporated
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Becton, Dickinson and Company
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. C.R. Bard, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 13 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 16 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 18 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 20 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 21 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 22 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 24 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 26 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 28 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 30 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 32 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 37 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 38 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 39 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 40 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 41 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 43 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 45 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 46 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 47 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 49 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 50 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 52 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
  • Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 breast cancer core needle biopsy market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Global breast cancer core needle biopsy market: Technology movement analysis
  • Fig. 15 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 16 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 17 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 18 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 19 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 20 Global breast cancer core needle biopsy market: End use movement analysis
  • Fig. 21 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
  • Fig. 22 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 23 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Regional outlook, 2024 & 2030
  • Fig. 26 Global breast cancer core needle biopsy market: Region movement analysis
  • Fig. 27 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 49 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 50 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 53 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 54 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)